Ticker

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Profitability This table compares Foghorn Therapeutics and

Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript

Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene autotemcel), the company's gene therapy for children with severe leukocyte adhesion deficiency-I (LAD-I) caused by biallelic variants in ITGB2. The therapy is intended for patients without an available human leukocyte antigen-matched sibling donor for allogeneic…

Rocket Pharmaceuticals shares jumped 10% on Friday before the bell after the U.S. Food and Drug Administration approved its ​gene therapy for a rare and often fatal immune ‌disorder in children, marking the first regulatory green light for a treatment of the condition.